Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: A modelling approach

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 2, 2007, Pages 385-393

  Ament, André J H A ^a   Hübben, Mariette W A ^a   Verweij, Paul E ^b   de Groot, Ronald ^b   Warris, Adillia ^b   Donnelly, Peter J ^b   van't Wout, Jan ^c   Severens, Johan L ^d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antifungal treatment; Cost effectiveness; Probabilistic sensitivity analysis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FOLLOW UP; GRAFT RECIPIENT; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOKALEMIA; LIFE EXPECTANCY; LONG TERM CARE; NEPHROTOXICITY; NETHERLANDS; PROBABILITY; SENSITIVITY ANALYSIS; SURVIVAL TIME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DATA INTERPRETATION, STATISTICAL; DECISION TREES; DRUG COMBINATIONS; ECHINOCANDINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MODELS, ECONOMIC; MODELS, STATISTICAL; NETHERLANDS; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 34547828220     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm196     Document Type: Article

References (44)

1. Kaiser L, Huguenin T, Lew PD et al. Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine 1998; 77: 188-94.
2. Wald A, Leisenring W, van Burik JA et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-66.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 358-66.
4. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis. Rev Infect Dis 1990; 12: 1147-201.
5. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
6. Ellis D. Amphotericin B: Spectrum and resistance. J Antimicrob Chemother 2002; 49 Suppl 1: 7-10.
7. Leenders ACAP, Daenen S, Jansen RLH et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205-12.
8. Reichenberger F, Habicht JM, Gratwohl A. Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 2002; 19: 743-55.
9. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98: 292-9.
10. Ninin E, Milpied N, Moreau P et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin-Infect Dis 2001; 33: 41-7.
11. Pound MW, Drew RH, Perfect JR. Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. Curr Opin Infect Dis 2002; 15: 183-94.
12. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
13. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: An update. Eur J Clin Microbiol Infect Dis 2002; 21: 161-72.
14. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26 781-803.
15. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002; 35: 1073-80.
16. Dixon.S, McKeen E, Tabberer M et al. Economic evaluations of treatments for systemic fungal infections. PharmacoEconomics 2004; 22: 421-33.
17. Bennett JE, Powers J, Walsh T et al. Forum report: Issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003; 36: S117-S122.
18. Barret JP, Vardulaki KA, Conlon C et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25: 1295-1320.
19. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-57.
20. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37: S157-87.
21. Wenzel R, Del Favero A, Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005; 55: 352-61.
22. Severens JL, Donnelly JP, Meis JF et al. Two strategies for managing invasive aspergillosis: A decision analysis. Clin Infect Dis 1997; 25: 1148-54.
23. Denning DW. Echinocandins: A new class of antifungal. J Antimicrob, Chemother 2002; 49: 889-91.
24. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
25. Patterson TF. Early use of antifungal therapy in high-risk patients. Curr Opin Infect Dis 2002; 15: 561-3.
26. Ellis M. Amphotericin B and invasive aspergillosis - how do the data guide us? J Med Microbiol 2002; 51: 95-7.
27. Herbrecht R, Patterson TF, Bennett JE. Voriconazole versus amphotericin B for invasive aspergillosis; the authors reply. N Engl J Med 2002; 347: 2080-1.
28. Drummond MF, O'Brien BJ, Stoddart GL et al. Methods for the Economic Evaluation of Health Care Programmes, Second edition. Oxford: Oxford University Press, 1997.
29. Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406-12.
30. Oostenbrink J, Koopmanschap M, Rutten F. Handleiding voor kostenonderzoek. Amstelveen: College voor Zorgverzekeringen, 2000.
31. van Hout BA, Al MJ, Gordon GS et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309-19.
32. Stinnett AA, Mullahy J. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18: S68-80.
33. Briggs A, Sculpher M, Buxton M, Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ 1994; 3: 95-104.
34. Doubilet P, Begg CB, Weinstein MC et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 5: 157-77.
35. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-15.
36. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
37. Lewis JS, Boucher HW, Lubowski T et al. Economic advantage of voriconazole (VRC) for primary treatment of invasive aspergillosis compared to conventional amphotericin B (CAB). In: Abstracts of the Forly-third Inferscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract A-1359, p. 26. Washington, DC, USA: American Society for Microbiology.
38. Marbaix S, Marciniak A, De Mees V et al. Cost-effectiveness of voriconazole compared with conventional amphotericin B in first line treatment of invasive aspergillosis in Belgium. Value Health 2003; 6: 750.
39. Grau S, Mateu-de Antonio J, Soto J et al. Cost-effectiveness analysis of voriconazole versus amphotericin B in the treatment of invasive aspergillosis in Spain. Value Health 2003; 6: 750-1.
40. Jansen JP, Meis JF, Van't Wout JW et al. Economic evaluation of voriconazole in the treatment of invasive aspergillosis. In: Abstracts of the Ninth Congress of the European Confederation of Medical Mycology and Seventh Trends in Invasive Fungal Infections (ECMM/TIFI), Amsterdam, 2003. Abstract P022.
41. Kuti JL, Kotapati S, Williams P et al. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. PharmacoEconomics 2004; 22: 301-10.
42. Laupacis A, Feeny D, Detsky AS et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-81.
43. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Pol 1998; 44: 215-32.
44. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-66.